Semax Before the FDA: Cerebral Ischemia, Migraine and Trigeminal Neuralgia

Semax Before the FDA: Cerebral Ischemia, Migraine and Trigeminal Neuralgia

By the Generic Peptides Team

Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article covers a public regulatory proceeding and is not medical or legal advice. Semax is not approved by the FDA to treat cerebral ischemia, migraine, trigeminal neuralgia, or any other medical condition.

One peptide. Three neurological conditions. Three very different standards of proof.

On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee, known as PCAC, will discuss Semax free base and Semax acetate for possible inclusion on the 503A Bulks List.

The uses being evaluated are cerebral ischemia, migraine, and trigeminal neuralgia.

That list may make Semax sound like a general-purpose treatment for the brain. The available evidence tells a less tidy story. Most identifiable human research concerns ischemic stroke. The pain literature is much thinner, older, and harder to interpret.

There is also an essential regulatory distinction: these are uses proposed through the compounding nomination process. They are not FDA conclusions that Semax is safe, effective, or promising for any of them.

For the complete agenda, see our overview of the July 2026 FDA peptide meeting.

What Is Semax?

Semax is a synthetic heptapeptide, meaning that it contains seven amino acids. FDA's substance database gives its sequence as:

Met-Glu-His-Phe-Pro-Gly-Pro

It is often abbreviated as MEHFPGP.

The first four amino acids correspond to the ACTH(4-7) fragment. The final Pro-Gly-Pro sequence was added to produce a peptide with longer-lasting neurotropic activity. Although Semax was derived from part of adrenocorticotropic hormone, published research describes it as lacking the hormonal activity associated with full ACTH.

Researchers have investigated several possible effects, including changes involving brain-derived neurotrophic factor, or BDNF; inflammatory signaling; neurotransmitter systems; and gene expression after experimental brain ischemia.

Most of that mechanistic work was conducted in cells or animals.

This matters because a plausible biological mechanism can explain why researchers became interested in a peptide. It cannot establish that the peptide improves outcomes in people.

Why Cerebral Ischemia Is the Strongest Part of the Nomination

Cerebral ischemia occurs when part of the brain receives insufficient blood flow and oxygen. Ischemic stroke is its most urgent and familiar clinical form.

Semax has a real human research history in this area, but the record is concentrated in Russian-language studies and does not resemble the large, multinational development programs normally used to support a modern U.S. drug approval.

A 1997 comparative study evaluated Semax in 30 patients during the acute period of hemispheric ischemic stroke. The control group included 80 patients with strokes described as similar in severity and location who received conventional therapy.

The authors reported that adding Semax to intensive treatment appeared to accelerate recovery of neurological functions, particularly motor deficits.

Those findings are worth knowing. The limitations are equally important.

The English abstract does not describe a blinded, placebo-controlled design or clearly explain random allocation. The Semax group was also much smaller than the comparison group. Without full methodological detail, it is difficult to determine how well the study controlled for differences in baseline condition, supportive care, assessment, and recovery.

Another study examined possible immunobiochemical mechanisms during acute ischemic stroke. Later animal research reported changes in genes associated with inflammation, vascular function, neurotransmission, and cell stress after experimental cerebral ischemia.

These findings created a biologically coherent hypothesis: Semax might modify some of the secondary processes that occur after blood flow to brain tissue is interrupted.

Coherence is not confirmation. Changes in EEG findings, biomarkers, or gene expression do not automatically translate into less disability or better long-term survival.

The 2018 Rehabilitation Study Adds Data, but Not a Final Answer

A 2018 publication followed 110 patients after ischemic stroke. Participants entered rehabilitation at earlier or later stages, and each group included patients who did or did not receive Semax.

The researchers measured plasma BDNF, motor performance, and the Barthel Index, which assesses independence in everyday activities.

They reported that Semax administration increased BDNF levels and was associated with faster or better functional recovery.

This study is larger than many other human Semax reports. It also addresses rehabilitation rather than the immediate emergency treatment of an acute stroke.

Still, the abstract does not present the study as a large randomized, blinded, placebo-controlled trial. Rehabilitation timing, patient selection, baseline function, and other care can all influence recovery. A biomarker increase is also not the same as proof of clinical benefit.

The cerebral-ischemia evidence is therefore more substantial than the evidence for the other two nominated uses, but it remains difficult to translate directly into a conclusion about a compounded U.S. product.

An ischemic stroke is a medical emergency. Nothing about the July PCAC review changes the need for immediate emergency assessment or the evidence-based treatments used to restore blood flow and prevent another stroke.

Migraine Enters Through a Small and Old Pain Study

Migraine is not simply a severe headache. It is a complex neurological disorder involving altered sensory processing, trigeminal activation, and, in some patients, cortical spreading depolarization associated with aura.

Semax appears in the migraine discussion largely because of a short report published in 1996.

The paper, titled Analgesic Action of the New Drug Semax, described intranasal Semax in people with migraine headache and dental plexalgia, a chronic facial or dental pain syndrome. Its English abstract reported reduced pain after administration and proposed that the effect reflected broader regulatory or spasmolytic activity rather than a direct change in the pain-sensitivity system.

That report is the clearest direct human link between Semax and migraine in the readily identifiable literature.

It is also a very limited foundation for a migraine claim.

The publication is only a few pages long. The accessible abstract does not provide the level of detail expected from a modern migraine trial: clearly defined diagnostic criteria, randomization, blinding, placebo comparison, prespecified endpoints, attack freedom at standard time points, rescue-medication use, recurrence, and systematic adverse-event reporting.

Modern migraine trials are designed to distinguish a true treatment effect from spontaneous improvement, expectation, and the natural variability of an attack. A small report from 1996 cannot answer those questions by itself.

There is another reason to be cautious. Migraine treatment has changed substantially since the study appeared. Current research uses far more precise disease definitions and outcome measures, and the biology of the trigeminovascular system and CGRP signaling is much better understood.

The old report is evidence that Semax was tested in people with migraine. It is not independent confirmation that Semax is an effective migraine treatment.

Trigeminal Neuralgia Is a Separate Question

Trigeminal neuralgia causes sudden, severe, electric-shock-like facial pain. Classic cases are commonly associated with compression and focal demyelination of the trigeminal nerve near the brainstem.

That is not the same condition as migraine, even though both involve pathways connected to the trigeminal system.

The distinction matters because evidence cannot be transferred simply by sharing the word "trigeminal."

The 1996 Semax pain paper is sometimes summarized online as evidence for several facial pain conditions. Its accessible English abstract specifically mentions migraine headache and dental plexalgia. It does not provide a clearly described modern trial of Semax for conventionally diagnosed trigeminal neuralgia.

That leaves several questions for the FDA briefing documents:

• What evidence did the nominator submit specifically for trigeminal neuralgia?
• Were patients diagnosed using criteria that distinguish neuralgia from dental plexalgia or other facial pain?
• Was Semax tested against placebo or standard treatment?
• Were attack frequency, intensity, triggers, and duration measured separately?
• Did the evidence concern free-base Semax, Semax acetate, or a finished product whose identity may not match either nominated bulk substance?

Until the nomination materials and FDA review are public, trigeminal neuralgia should be treated as a proposed indication, not as a clinically established use.

Animal Analgesia Does Not Resolve the Pain Question

Animal experiments have produced mixed findings that depend partly on how Semax was administered.

A study of rats reported analgesic activity after intraperitoneal administration. In the same work, intranasal Semax improved performance in a learning task but did not change pain sensitivity.

This is not merely an academic detail. Route-dependent results make it risky to combine all Semax studies into one general claim that the peptide "reduces pain."

Pain from a compressed or demyelinated trigeminal nerve is also more specific than a laboratory paw-pressure, hot-plate, or chemically induced pain response. Animal models can identify possible mechanisms, but they do not substitute for controlled trials in people with a well-defined neurological diagnosis.

Human Exposure Exists, but the Safety Record Is Still Limited

Semax differs from peptides for which no published human administration can be found.

It has appeared in stroke studies, pain research, small experiments in healthy volunteers, and an fMRI study examining changes in the brain's default mode network after intranasal administration.

That does not automatically provide the safety information FDA needs for the current nomination.

FDA states:

Compounded drugs containing Semax may pose a risk of immunogenicity for certain routes because of potential aggregation and peptide-related impurities.

The agency also says it has no, or limited, safety-related information for the proposed routes of administration and therefore lacks enough information to know whether the drug would cause harm when administered to humans.

This wording is narrower than saying Semax has never been given to people. Human exposure exists.

The unresolved issue is whether published reports adequately characterize safety for the exact substance, route, formulation, concentration, manufacturing process, and pattern of use under review.

Older clinical publications often provide only brief adverse-event reporting. They may not establish whether the material was free-base Semax, an acetate form, or a preparation analytically comparable to a currently compounded product.

For a peptide, those details affect more than labeling. Aggregation, impurities, stability, and product characterization can influence immunogenicity and exposure.

Free Base and Acetate Cannot Be Treated as Interchangeable by Default

PCAC is scheduled to discuss two related bulk drug substances:

• Semax free base;
• Semax acetate.

An acetate salt may improve handling or formulation, but it does not erase the need to identify what was used in earlier research.

If a paper refers only to "Semax," the name alone may not establish which chemical form, purity profile, excipients, or manufacturing controls were involved. The same uncertainty applies when an older study evaluates a finished nasal product but the current proceeding concerns a bulk ingredient used in compounding.

The committee must connect evidence to the actual substance under review. A clinical result cannot simply be assigned to both forms without adequate chemical and pharmaceutical support.

What Happened to Category 2?

Semax previously appeared in Category 2 of FDA's interim 503A policy, which covered nominated substances associated with potentially significant safety concerns.

By April 22, 2026, FDA listed Semax in its separate table of bulk substances whose previous nominations had been withdrawn rather than in the active Category 2 table. Separately, FDA scheduled Semax free base and Semax acetate for formal PCAC review.

Those events are not contradictory.

The withdrawn entry concerns the status of an earlier nomination. The July meeting is a new public evaluation of the two listed Semax forms for the three proposed uses.

Removal from the active Category 2 table did not approve Semax, resolve FDA's safety concerns, or place either form on the 503A Bulks List.

The Question Is Not Whether Semax Has Been Studied

It has.

The harder question is whether the studies answer the specific regulatory problem before PCAC.

FDA generally considers four broad areas when evaluating a substance for the 503A Bulks List:

1. Physical and chemical characterization.
2. Safety when used in compounded drug products.
3. Evidence of effectiveness.
4. Historical use in compounding.

Semax presents a lopsided record.

For cerebral ischemia, there are comparative human studies, rehabilitation data, biomarkers, and a substantial body of animal mechanism research. However, much of the clinical evidence is difficult to evaluate against current trial standards.

For migraine, the direct human evidence appears to rest heavily on a short 1996 pain report.

For trigeminal neuralgia, the publicly identifiable clinical basis is less clear still.

That imbalance should matter. Three indications on one meeting agenda do not become one combined vote of confidence in "brain health."

What the July Recommendation Could Mean

FDA will release the final voting questions with the meeting materials. Depending on their wording, the committee may consider the free-base and acetate forms separately, and its conclusions may differ by indication or route.

A recommendation for inclusion would not constitute FDA approval of Semax. It would not establish that the peptide prevents stroke disability, stops migraine attacks, or treats trigeminal neuralgia.

FDA would still need to consider the committee's advice and proceed through notice-and-comment rulemaking. That process can take months or years.

If a Semax form is eventually added to the 503A Bulks List, qualifying compounded drugs made from it could be eligible for certain statutory exemptions only when all other requirements of section 503A are satisfied.

If FDA ultimately decides against inclusion, compounded products made from that bulk substance would not qualify for those exemptions under section 503A.

PCAC advises FDA. It does not approve drugs, license vendors, or settle every legal question surrounding a product.

What to Watch on July 24

FDA plans to publish briefing documents no later than two business days before the meeting. For Semax, the most revealing details should be:

• the exact nominated routes and dosage forms;
• the source and design of evidence for each indication;
• whether FDA can identify the chemical form used in older studies;
• how the agency evaluates the 1997 stroke comparison;
• whether the 2018 rehabilitation study was sufficiently controlled;
• the full data behind the 1996 migraine and facial-pain report;
• whether distinct trigeminal-neuralgia evidence exists;
• what repeated-use and route-specific safety information is available;
• whether the free base and acetate receive separate voting questions.

Public comments may be submitted to docket FDA-2025-N-6895 until 11:59 p.m. Eastern Time on July 22, 2026. Comments received by July 9 will be provided to the committee before the meeting.

The July 24 session is scheduled for 8:00 a.m. to 3:50 p.m. Eastern Time and will include an online viewing option.

The Bottom Line

Semax is not a peptide with no human evidence. That would be the wrong criticism.

Its real problem is uneven evidence. Cerebral ischemia has a recognizable clinical and experimental research history. Migraine relies on a small, old pain report. The public case for trigeminal neuralgia remains difficult to see.

The July review will test whether that record is strong enough, specific enough, and chemically relevant enough for either Semax form to qualify for the 503A Bulks List.

The meeting is not a referendum on whether Semax is an interesting molecule. It is a test of whether interesting research has become dependable evidence.

---